Clinical trial

A Phase II Study Evaluating Intravenous Melphalan With Autologous Whole Blood Stem Cell Transplantation Over Three Cycles In Patients With Castration-Resistant Prostate Cancer (MEL-CAP)

NCT01907009

Study summary

ClinicalTrials.gov

A Phase II Study Evaluating Intravenous Melphalan With Autologous Whole Blood Stem Cell Transplantation Over Three Cycles In Patients With Castration-Resistant Prostate Cancer (MEL-CAP)

Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE2, PHASE3

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Mapped RxNorm record Melphalan Normalized identity: melphalan View linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Lenograstim Find medicine records · Find other trials using this name

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2013-01-01

PhasePHASE2 / PHASE3

Conditions

Castrate Resistant Prostate Cancerunresolved

Interventions

MelphalanDRUG · verified · RxNorm: melphalan

LenograstimDRUG

Sponsors & collaborators

Barts & The London NHS Trustlead sponsor

Mapped research locations

LondonUnited Kingdom1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01907009 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.